MedTrace Logo

A Clinical Trial to Assess the Absorption, Safety, and Efficacy of an Oral Nicotinamide Adenine Dinucleotide (NAD+) Supplement in Healthy Adults

NCT07692633 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-08-11

No results posted yet for this study

Summary

The goal of this clinical trial is to assess the absorption, safety, and efficacy of an NAD+ supplement in healthy adults. The main question it aims to answer is: What is the change in NAD+ levels in whole blood from baseline to day 56 between the NAD+ supplement and placebo? Researchers will compare the NAD+ supplement to placebo to evaluate its absorption, safety, and efficacy. Participants will be asked to:

* Complete questionnaires
* Provide blood samples
* Consume either the NAD+ supplement or a placebo for 55 days
* Have their endothelial function evaluated

Conditions

  • NAD+ Bioavailability
  • NAD+ Safety
  • NAD+ Efficacy

Interventions

DIETARY_SUPPLEMENT

NAD+

Participants will be instructed to take two capsules daily after breakfast starting on Day 1 (day following baseline visit) until the day prior to their end of study visit.

DIETARY_SUPPLEMENT

Placebo

Participants will be instructed to take two capsules daily after breakfast starting on Day 1 (day following baseline visit) until the day prior to their end of study visit.

Sponsors & Collaborators

  • KGK Science Inc.

    collaborator INDUSTRY

  • Reus Research

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2027-03-31
Completion
2027-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07692633 on ClinicalTrials.gov